Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications

作者：Ying Guo, Xudong Wang, Chen Zhang, Weiwu Chen, Yutian Fu, Yanlan Yu, Yicheng Chen, Tiejuan Shao, Jie Zhang, Guoqing Ding · 发表于：ImmunoTargets and Therapy · 年份：2025 · DOI：10.2147/itt.s507522 · 被引用次数：25 · 研究领域：Nanoplatforms for cancer theranostics、Cancer Immunotherapy and Biomarkers、RNA Interference and Gene Delivery

B7-H3 (CD276) is an immune checkpoint from the B7 family of molecules and is abnormally expressed in tumor cells as a co-inhibitory molecule to promote tumor progression. Within the tumor microenvironment (TME), B7-H3 promotes tumor progression by impairing the T cell response, driving the polarization of tumor-associated macrophages (TAMs) to M2 phenotype, and inhibiting the function of other immune cells. In addition, B7-H3 promotes tumor cell proliferation, migration, invasion, metabolism disorder, angiogenesis, and resistance to treatment to promote tumor progression through its non-immunological functions. Immunotherapy targeting B7-H3, as well as combinations with other immune checkpoint therapies, have shown certain efficacy. In this review, we synthesizes the expression of B7-H3 and its mechanism to promote tumor progression through inducing immunomodulation and non-immunological functions, as well as its role of B7-H3 in tumor therapy, aiming to provide a reference for the clinical treatment of tumors.